APO Research
Talk to an analyst

APO RESEARCH · REPORT

Insulin Glargine and Lispro

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Insulin Glargine and Lispro Industry Growth and Trends Forecast to 2032

31 December 2025106 pages

Choose your research edition.

Industry ResearchInsulin Glargine and Lispro Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Insulin Glargine and Lispro Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal Insulin Glargine and Lispro Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Insulin Glargine and Lispro Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Insulin Glargine and Lispro Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Insulin Glargine and Lispro market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Insulin Glargine and Lispro is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Insulin Glargine and Lispro is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Insulin Glargine and Lispro is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Insulin Glargine and Lispro include Sanofi S.A, Merck & Co., Eli Lilly and Company, Wockhardt Ltd., SAJA Pharmaceuticals, Novo Nordisk A/S, Julphar Diabetes LLC, Gan & Lee Pharmaceutical Ltd. and Cipla Limited, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Insulin Glargine and Lispro market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Insulin Glargine and Lispro market size, estimates, and forecasts are presented in terms of sales volume (L) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Insulin Glargine and Lispro market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Insulin Glargine and Lispro.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Insulin Glargine and Lispro market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Insulin Glargine and Lispro Market by Company

Sanofi S.A

Merck & Co.

Eli Lilly and Company

Wockhardt Ltd.

SAJA Pharmaceuticals

Novo Nordisk A/S

Julphar Diabetes LLC

Gan & Lee Pharmaceutical Ltd.

Cipla Limited

Biocon Limited

Insulin Glargine and Lispro Segment by Type

Branded Drug

Biosimilar Drug

Insulin Glargine and Lispro Segment by Application

Type I Dibetes

Type II Dibetes

Insulin Glargine and Lispro Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Insulin Glargine and Lispro market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Insulin Glargine and Lispro and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Insulin Glargine and Lispro.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Insulin Glargine and Lispro manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Insulin Glargine and Lispro in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Branded Drug Table 2. Major Company of Biosimilar Drug Table 3. Global Insulin Glargine and Lispro Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Insulin Glargine and Lispro Sales by Type (2021-2026) & (L) Table 5. Global Insulin Glargine and Lispro Sales Market Share in Volume by Type (2021-2026) Table 6. Global Insulin Glargine and Lispro Sales by Type (2021-2026) & (US$ Million) Table 7. Global Insulin Glargine and Lispro Sales Market Share in Value by Type (2021-2026) Table 8. Global Insulin Glargine and Lispro Price by Type (2021-2026) & (US$/ml) Table 9. Global Insulin Glargine and Lispro Sales by Type (2027-2032) & (L) Table 10. Global Insulin Glargine and Lispro Sales Market Share in Volume by Type (2027-2032) Table 11. Global Insulin Glargine and Lispro Sales by Type (2027-2032) & (US$ Million) Table 12. Global Insulin Glargine and Lispro Sales Market Share in Value by Type (2027-2032) Table 13. Global Insulin Glargine and Lispro Price by Type (2027-2032) & (US$/ml) Table 14. North America Insulin Glargine and Lispro Sales by Type (2021-2026) & (L) Table 15. North America Insulin Glargine and Lispro Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Insulin Glargine and Lispro Sales by Type (2021-2026) & (L) Table 17. Europe Insulin Glargine and Lispro Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Insulin Glargine and Lispro Sales by Type (2021-2026) & (L) Table 19. Asia-Pacific Insulin Glargine and Lispro Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Insulin Glargine and Lispro Sales by Type (2021-2026) & (L) Table 21. Latin America Insulin Glargine and Lispro Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Insulin Glargine and Lispro Sales by Type (2021-2026) & (L) Table 23. Middle East and Africa Insulin Glargine and Lispro Sales by Type (2021-2026) & (US$ Million) Table 24. Insulin Glargine and Lispro Industry Trends Table 25. Insulin Glargine and Lispro Industry Drivers Table 26. Insulin Glargine and Lispro Industry Opportunities and Challenges Table 27. Insulin Glargine and Lispro Industry Restraints Table 28. Global Insulin Glargine and Lispro Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Insulin Glargine and Lispro Revenue Market Share by Company (2021-2026) Table 30. Global Insulin Glargine and Lispro Sales by Company (2021-2026) & (L) Table 31. Global Insulin Glargine and Lispro Sales Share by Company (2021-2026) Table 32. Global Insulin Glargine and Lispro Market Price by Company (2021-2026) & (US$/ml) Table 33. Global Insulin Glargine and Lispro Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Insulin Glargine and Lispro Major Company Production Sites and Headquarters Table 35. Global Insulin Glargine and Lispro Company, Product Type & Application Table 36. Global Insulin Glargine and Lispro Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Insulin Glargine and Lispro by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Insulin Glargine and Lispro Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Insulin Glargine and Lispro Sales by Region (2021-2026) & (L) Table 41. Global Insulin Glargine and Lispro Sales Market Share in Volume by Region (2021-2026) Table 42. Global Insulin Glargine and Lispro Sales by Region (2021-2026) & (US$ Million) Table 43. Global Insulin Glargine and Lispro Sales Market Share in Value by Region (2021-2026) Table 44. Global Insulin Glargine and Lispro Sales (L), Value (US$ Million), Price (US$/ml) and Gross Margin (2021-2026) Table 45. Global Insulin Glargine and Lispro Sales by Region (2027-2032) & (L) Table 46. Global Insulin Glargine and Lispro Sales Market Share in Volume by Region (2027-2032) Table 47. Global Insulin Glargine and Lispro Sales by Region (2027-2032) & (US$ Million) Table 48. Global Insulin Glargine and Lispro Sales Market Share in Value by Region (2027-2032) Table 49. Global Insulin Glargine and Lispro Sales (L), Value (US$ Million), Price (US$/ml) and Gross Margin (2027-2032) Table 50. Global Insulin Glargine and Lispro Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Insulin Glargine and Lispro Sales by Application (2021-2026) & (L) Table 52. Global Insulin Glargine and Lispro Sales Market Share in Volume by Application (2021-2026) Table 53. Global Insulin Glargine and Lispro Sales by Application (2021-2026) & (US$ Million) Table 54. Global Insulin Glargine and Lispro Sales Market Share in Value by Application (2021-2026) Table 55. Global Insulin Glargine and Lispro Price by Application (2021-2026) & (US$/ml) Table 56. Global Insulin Glargine and Lispro Sales by Application (2027-2032) & (L) Table 57. Global Insulin Glargine and Lispro Sales Market Share in Volume by Application (2027-2032) Table 58. Global Insulin Glargine and Lispro Sales by Application (2027-2032) & (US$ Million) Table 59. Global Insulin Glargine and Lispro Sales Market Share in Value by Application (2027-2032) Table 60. Global Insulin Glargine and Lispro Price by Application (2027-2032) & (US$/ml) Table 61. North America Insulin Glargine and Lispro Sales by Application (2021-2026) & (L) Table 62. North America Insulin Glargine and Lispro Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Insulin Glargine and Lispro Sales by Application (2021-2026) & (L) Table 64. Europe Insulin Glargine and Lispro Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Insulin Glargine and Lispro Sales by Application (2021-2026) & (L) Table 66. Asia-Pacific Insulin Glargine and Lispro Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Insulin Glargine and Lispro Sales by Application (2021-2026) & (L) Table 68. Latin America Insulin Glargine and Lispro Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Insulin Glargine and Lispro Sales by Application (2021-2026) & (L) Table 70. Middle East and Africa Insulin Glargine and Lispro Sales by Application (2021-2026) & (US$ Million) Table 71. Sanofi S.A Company Information Table 72. Sanofi S.A Business Overview Table 73. Sanofi S.A Insulin Glargine and Lispro Sales (L), Revenue (US$ Million), Price (US$/ml) and Gross Margin (2021-2026) Table 74. Sanofi S.A Insulin Glargine and Lispro Product Portfolio Table 75. Sanofi S.A Recent Development Table 76. Merck & Co. Company Information Table 77. Merck & Co. Business Overview Table 78. Merck & Co. Insulin Glargine and Lispro Sales (L), Revenue (US$ Million), Price (US$/ml) and Gross Margin (2021-2026) Table 79. Merck & Co. Insulin Glargine and Lispro Product Portfolio Table 80. Merck & Co. Recent Development Table 81. Eli Lilly and Company Company Information Table 82. Eli Lilly and Company Business Overview Table 83. Eli Lilly and Company Insulin Glargine and Lispro Sales (L), Revenue (US$ Million), Price (US$/ml) and Gross Margin (2021-2026) Table 84. Eli Lilly and Company Insulin Glargine and Lispro Product Portfolio Table 85. Eli Lilly and Company Recent Development Table 86. Wockhardt Ltd. Company Information Table 87. Wockhardt Ltd. Business Overview Table 88. Wockhardt Ltd. Insulin Glargine and Lispro Sales (L), Revenue (US$ Million), Price (US$/ml) and Gross Margin (2021-2026) Table 89. Wockhardt Ltd. Insulin Glargine and Lispro Product Portfolio Table 90. Wockhardt Ltd. Recent Development Table 91. SAJA Pharmaceuticals Company Information Table 92. SAJA Pharmaceuticals Business Overview Table 93. SAJA Pharmaceuticals Insulin Glargine and Lispro Sales (L), Revenue (US$ Million), Price (US$/ml) and Gross Margin (2021-2026) Table 94. SAJA Pharmaceuticals Insulin Glargine and Lispro Product Portfolio Table 95. SAJA Pharmaceuticals Recent Development Table 96. Novo Nordisk A/S Company Information Table 97. Novo Nordisk A/S Business Overview Table 98. Novo Nordisk A/S Insulin Glargine and Lispro Sales (L), Revenue (US$ Million), Price (US$/ml) and Gross Margin (2021-2026) Table 99. Novo Nordisk A/S Insulin Glargine and Lispro Product Portfolio Table 100. Novo Nordisk A/S Recent Development Table 101. Julphar Diabetes LLC Company Information Table 102. Julphar Diabetes LLC Business Overview Table 103. Julphar Diabetes LLC Insulin Glargine and Lispro Sales (L), Revenue (US$ Million), Price (US$/ml) and Gross Margin (2021-2026) Table 104. Julphar Diabetes LLC Insulin Glargine and Lispro Product Portfolio Table 105. Julphar Diabetes LLC Recent Development Table 106. Gan & Lee Pharmaceutical Ltd. Company Information Table 107. Gan & Lee Pharmaceutical Ltd. Business Overview Table 108. Gan & Lee Pharmaceutical Ltd. Insulin Glargine and Lispro Sales (L), Revenue (US$ Million), Price (US$/ml) and Gross Margin (2021-2026) Table 109. Gan & Lee Pharmaceutical Ltd. Insulin Glargine and Lispro Product Portfolio Table 110. Gan & Lee Pharmaceutical Ltd. Recent Development Table 111. Cipla Limited Company Information Table 112. Cipla Limited Business Overview Table 113. Cipla Limited Insulin Glargine and Lispro Sales (L), Revenue (US$ Million), Price (US$/ml) and Gross Margin (2021-2026) Table 114. Cipla Limited Insulin Glargine and Lispro Product Portfolio Table 115. Cipla Limited Recent Development Table 116. Biocon Limited Company Information Table 117. Biocon Limited Business Overview Table 118. Biocon Limited Insulin Glargine and Lispro Sales (L), Revenue (US$ Million), Price (US$/ml) and Gross Margin (2021-2026) Table 119. Biocon Limited Insulin Glargine and Lispro Product Portfolio Table 120. Biocon Limited Recent Development Table 121. North America Insulin Glargine and Lispro Market Size Growth Rate (CAGR) by Country (L): 2021 VS 2025 VS 2032 Table 122. North America Insulin Glargine and Lispro Sales by Country (2021-2026) & (L) Table 123. North America Insulin Glargine and Lispro Sales Market Share by Country (2021-2026) Table 124. North America Insulin Glargine and Lispro Sales Forecast by Country (2027-2032) & (L) Table 125. North America Insulin Glargine and Lispro Sales Market Share Forecast by Country (2027-2032) Table 126. North America Insulin Glargine and Lispro Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 127. North America Insulin Glargine and Lispro Market Size by Country (2021-2026) & (US$ Million) Table 128. North America Insulin Glargine and Lispro Market Share by Country (2021-2026) Table 129. North America Insulin Glargine and Lispro Market Size Forecast by Country (2027-2032) & (US$ Million) Table 130. North America Insulin Glargine and Lispro Market Share Forecast by Country (2027-2032) Table 131. Europe Insulin Glargine and Lispro Market Size Growth Rate (CAGR) by Country (L): 2021 VS 2025 VS 2032 Table 132. Europe Insulin Glargine and Lispro Sales by Country (2021-2026) & (L) Table 133. Europe Insulin Glargine and Lispro Sales Market Share by Country (2021-2026) Table 134. Europe Insulin Glargine and Lispro Sales Forecast by Country (2027-2032) & (L) Table 135. Europe Insulin Glargine and Lispro Sales Market Share Forecast by Country (2027-2032) Table 136. Europe Insulin Glargine and Lispro Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 137. Europe Insulin Glargine and Lispro Market Size by Country (2021-2026) & (US$ Million) Table 138. Europe Insulin Glargine and Lispro Market Share by Country (2021-2026) Table 139. Europe Insulin Glargine and Lispro Market Size Forecast by Country (2027-2032) & (US$ Million) Table 140. Europe Insulin Glargine and Lispro Market Share Forecast by Country (2027-2032) Table 141. Asia-Pacific Insulin Glargine and Lispro Market Size Growth Rate (CAGR) by Country (L): 2021 VS 2025 VS 2032 Table 142. Asia-Pacific Insulin Glargine and Lispro Sales by Country (2021-2026) & (L) Table 143. Asia-Pacific Insulin Glargine and Lispro Sales Market Share by Country (2021-2026) Table 144. Asia-Pacific Insulin Glargine and Lispro Sales Forecast by Country (2027-2032) & (L) Table 145. Asia-Pacific Insulin Glargine and Lispro Sales Market Share Forecast by Country (2027-2032) Table 146. Asia-Pacific Insulin Glargine and Lispro Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 147. Asia-Pacific Insulin Glargine and Lispro Market Size by Country (2021-2026) & (US$ Million) Table 148. Asia-Pacific Insulin Glargine and Lispro Market Share by Country (2021-2026) Table 149. Asia-Pacific Insulin Glargine and Lispro Market Size Forecast by Country (2027-2032) & (US$ Million) Table 150. Asia-Pacific Insulin Glargine and Lispro Market Share Forecast by Country (2027-2032) Table 151. Latin America Insulin Glargine and Lispro Market Size Growth Rate (CAGR) by Country (L): 2021 VS 2025 VS 2032 Table 152. Latin America Insulin Glargine and Lispro Sales by Country (2021-2026) & (L) Table 153. Latin America Insulin Glargine and Lispro Sales Market Share by Country (2021-2026) Table 154. Latin America Insulin Glargine and Lispro Sales Forecast by Country (2027-2032) & (L) Table 155. Latin America Insulin Glargine and Lispro Sales Market Share Forecast by Country (2027-2032) Table 156. Latin America Insulin Glargine and Lispro Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 157. Latin America Insulin Glargine and Lispro Market Size by Country (2021-2026) & (US$ Million) Table 158. Latin America Insulin Glargine and Lispro Market Share by Country (2021-2026) Table 159. Latin America Insulin Glargine and Lispro Market Size Forecast by Country (2027-2032) & (US$ Million) Table 160. Latin America Insulin Glargine and Lispro Market Share Forecast by Country (2027-2032) Table 161. Middle East and Africa Insulin Glargine and Lispro Market Size Growth Rate (CAGR) by Country (L): 2021 VS 2025 VS 2032 Table 162. Middle East and Africa Insulin Glargine and Lispro Sales by Country (2021-2026) & (L) Table 163. Middle East and Africa Insulin Glargine and Lispro Sales Market Share by Country (2021-2026) Table 164. Middle East and Africa Insulin Glargine and Lispro Sales Forecast by Country (2027-2032) & (L) Table 165. Middle East and Africa Insulin Glargine and Lispro Sales Market Share Forecast by Country (2027-2032) Table 166. Middle East and Africa Insulin Glargine and Lispro Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 167. Middle East and Africa Insulin Glargine and Lispro Market Size by Country (2021-2026) & (US$ Million) Table 168. Middle East and Africa Insulin Glargine and Lispro Market Share by Country (2021-2026) Table 169. Middle East and Africa Insulin Glargine and Lispro Market Size Forecast by Country (2027-2032) & (US$ Million) Table 170. Middle East and Africa Insulin Glargine and Lispro Market Share Forecast by Country (2027-2032) Table 171. Key Raw Materials Table 172. Raw Materials Key Suppliers Table 173. Insulin Glargine and Lispro Distributors List Table 174. Insulin Glargine and Lispro Customers List Table 175. Research Programs/Design for This Report Table 176. Authors List of This Report Table 177. Secondary Sources Table 178. Primary Sources List of Figures Figure 1. Insulin Glargine and Lispro Image Figure 2. Global Insulin Glargine and Lispro Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Insulin Glargine and Lispro Market Size (2021-2032) & (US$ Million) Figure 4. Global Insulin Glargine and Lispro Sales (2021-2032) & (L) Figure 5. Branded Drug Image Figure 6. Global Branded Drug Sales YoY Growth (2021-2032) & (L) Figure 7. Biosimilar Drug Image Figure 8. Global Biosimilar Drug Sales YoY Growth (2021-2032) & (L) Figure 9. Global Insulin Glargine and Lispro Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Insulin Glargine and Lispro Market Share by Type 2025 VS 2032 Figure 11. North America Insulin Glargine and Lispro Sales Market Share in Volume by Type in 2025 Figure 12. North America Insulin Glargine and Lispro Sales Market Share in Value by Type in 2025 Figure 13. Europe Insulin Glargine and Lispro Sales Market Share in Volume by Type in 2025 Figure 14. Europe Insulin Glargine and Lispro Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Insulin Glargine and Lispro Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Insulin Glargine and Lispro Sales Market Share in Value by Type in 2025 Figure 17. Latin America Insulin Glargine and Lispro Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Insulin Glargine and Lispro Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Insulin Glargine and Lispro Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Insulin Glargine and Lispro Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Insulin Glargine and Lispro Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Type I Dibetes Image Figure 24. Global Type I Dibetes Sales YoY Growth (2021-2032) & (L) Figure 25. Type II Dibetes Image Figure 26. Global Type II Dibetes Sales YoY Growth (2021-2032) & (L) Figure 27. Global Insulin Glargine and Lispro Market Size Overview by Application (2021-2032) & (US$ Million) Figure 28. Global Insulin Glargine and Lispro Market Share by Application 2025 VS 2032 Figure 29. North America Insulin Glargine and Lispro Sales Market Share in Volume by Application in 2025 Figure 30. North America Insulin Glargine and Lispro Sales Market Share in Value by Application in 2025 Figure 31. Europe Insulin Glargine and Lispro Sales Market Share in Volume by Application in 2025 Figure 32. Europe Insulin Glargine and Lispro Sales Market Share in Value by Application in 2025 Figure 33. Asia-Pacific Insulin Glargine and Lispro Sales Market Share in Volume by Application in 2025 Figure 34. Asia-Pacific Insulin Glargine and Lispro Sales Market Share in Value by Application in 2025 Figure 35. Latin America Insulin Glargine and Lispro Sales Market Share in Volume by Application in 2025 Figure 36. Latin America Insulin Glargine and Lispro Sales Market Share in Value by Application in 2025 Figure 37. Middle East and Africa Insulin Glargine and Lispro Sales Market Share in Volume by Application in 2025 Figure 38. Middle East and Africa Insulin Glargine and Lispro Sales Market Share in Value by Application in 2025 Figure 39. North America Insulin Glargine and Lispro Sales by Country: 2021 VS 2025 VS 2032 (L) Figure 40. North America Insulin Glargine and Lispro Sales Share by Country: 2021 VS 2025 VS 2032 Figure 41. North America Insulin Glargine and Lispro Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 42. North America Insulin Glargine and Lispro Market Share by Country: 2021 VS 2025 VS 2032 Figure 43. Europe Insulin Glargine and Lispro Sales by Country: 2021 VS 2025 VS 2032 (L) Figure 44. Europe Insulin Glargine and Lispro Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Insulin Glargine and Lispro Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. Europe Insulin Glargine and Lispro Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Asia-Pacific Insulin Glargine and Lispro Sales by Country: 2021 VS 2025 VS 2032 (L) Figure 48. Asia-Pacific Insulin Glargine and Lispro Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Insulin Glargine and Lispro Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Asia-Pacific Insulin Glargine and Lispro Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Latin America Insulin Glargine and Lispro Sales by Country: 2021 VS 2025 VS 2032 (L) Figure 52. Latin America Insulin Glargine and Lispro Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Insulin Glargine and Lispro Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Latin America Insulin Glargine and Lispro Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Middle East and Africa Insulin Glargine and Lispro Sales by Country: 2021 VS 2025 VS 2032 (L) Figure 56. Middle East and Africa Insulin Glargine and Lispro Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Insulin Glargine and Lispro Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Middle East and Africa Insulin Glargine and Lispro Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Insulin Glargine and Lispro Value Chain Figure 60. Key Raw Materials Price Figure 61. Manufacturing Cost Structure Figure 62. Insulin Glargine and Lispro Production Mode & Process Figure 63. Direct Comparison with Distribution Share Figure 64. Distributors Profiles Figure 65. Years Considered Figure 66. Research Process Figure 67. Key Executives Interviewed

Scope & coverage.

Types
  • Branded Drug
  • Biosimilar Drug
Applications
  • Type I Dibetes
  • Type II Dibetes
Companies covered
  • Sanofi S.A
  • Merck & Co.
  • Eli Lilly and Company
  • Wockhardt Ltd.
  • SAJA Pharmaceuticals
  • Novo Nordisk A/S
  • Julphar Diabetes LLC
  • Gan & Lee Pharmaceutical Ltd.
  • Cipla Limited
  • Biocon Limited

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Insulin Glargine and Lispro Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Insulin Glargine and Lispro Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Insulin Glargine and Lispro Market by Type
  6. 1.3.1 Branded Drug
  7. 1.3.2 Biosimilar Drug
  8. 1.4 Global Insulin Glargine and Lispro Market Size by Type
  9. 1.4.1 Global Insulin Glargine and Lispro Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Insulin Glargine and Lispro Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Insulin Glargine and Lispro Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Insulin Glargine and Lispro Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Insulin Glargine and Lispro Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Insulin Glargine and Lispro Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Insulin Glargine and Lispro Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Insulin Glargine and Lispro Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Insulin Glargine and Lispro Industry Trends
  2. 2.2 Insulin Glargine and Lispro Industry Drivers
  3. 2.3 Insulin Glargine and Lispro Industry Opportunities and Challenges
  4. 2.4 Insulin Glargine and Lispro Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Insulin Glargine and Lispro Revenue (2021-2026)
  2. 3.2 Global Top Players by Insulin Glargine and Lispro Sales (2021-2026)
  3. 3.3 Global Top Players by Insulin Glargine and Lispro Price (2021-2026)
  4. 3.4 Global Insulin Glargine and Lispro Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Insulin Glargine and Lispro Major Company Production Sites & Headquarters
  6. 3.6 Global Insulin Glargine and Lispro Company, Product Type & Application
  7. 3.7 Global Insulin Glargine and Lispro Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Insulin Glargine and Lispro Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Insulin Glargine and Lispro Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Insulin Glargine and Lispro Tier 1, Tier 2, and Tier 3
4 Insulin Glargine and Lispro Regional Status and Outlook
  1. 4.1 Global Insulin Glargine and Lispro Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Insulin Glargine and Lispro Historic Market Size by Region
  3. 4.2.1 Global Insulin Glargine and Lispro Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Insulin Glargine and Lispro Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Insulin Glargine and Lispro Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Insulin Glargine and Lispro Forecasted Market Size by Region
  7. 4.3.1 Global Insulin Glargine and Lispro Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Insulin Glargine and Lispro Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Insulin Glargine and Lispro Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Insulin Glargine and Lispro by Application
  1. 5.1 Insulin Glargine and Lispro Market by Application
  2. 5.1.1 Type I Dibetes
  3. 5.1.2 Type II Dibetes
  4. 5.2 Global Insulin Glargine and Lispro Market Size by Application
  5. 5.2.1 Global Insulin Glargine and Lispro Market Size Overview by Application (2021-2032)
  6. 5.2.2 Global Insulin Glargine and Lispro Historic Market Size Review by Application (2021-2026)
  7. 5.2.3 Global Insulin Glargine and Lispro Forecasted Market Size by Application (2027-2032)
  8. 5.3 Key Regions Market Size by Application
  9. 5.3.1 North America Insulin Glargine and Lispro Sales Breakdown by Application (2021-2026)
  10. 5.3.2 Europe Insulin Glargine and Lispro Sales Breakdown by Application (2021-2026)
  11. 5.3.3 Asia-Pacific Insulin Glargine and Lispro Sales Breakdown by Application (2021-2026)
  12. 5.3.4 South America Insulin Glargine and Lispro Sales Breakdown by Application (2021-2026)
  13. 5.3.5 Middle East and Africa Insulin Glargine and Lispro Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Sanofi S.A
  2. 6.1.1 Sanofi S.A Company Information
  3. 6.1.2 Sanofi S.A Business Overview
  4. 6.1.3 Sanofi S.A Insulin Glargine and Lispro Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Sanofi S.A Insulin Glargine and Lispro Product Portfolio
  6. 6.1.5 Sanofi S.A Recent Developments
  7. 6.2 Merck & Co.
  8. 6.2.1 Merck & Co. Company Information
  9. 6.2.2 Merck & Co. Business Overview
  10. 6.2.3 Merck & Co. Insulin Glargine and Lispro Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Merck & Co. Insulin Glargine and Lispro Product Portfolio
  12. 6.2.5 Merck & Co. Recent Developments
  13. 6.3 Eli Lilly and Company
  14. 6.3.1 Eli Lilly and Company Company Information
  15. 6.3.2 Eli Lilly and Company Business Overview
  16. 6.3.3 Eli Lilly and Company Insulin Glargine and Lispro Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Eli Lilly and Company Insulin Glargine and Lispro Product Portfolio
  18. 6.3.5 Eli Lilly and Company Recent Developments
  19. 6.4 Wockhardt Ltd.
  20. 6.4.1 Wockhardt Ltd. Company Information
  21. 6.4.2 Wockhardt Ltd. Business Overview
  22. 6.4.3 Wockhardt Ltd. Insulin Glargine and Lispro Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Wockhardt Ltd. Insulin Glargine and Lispro Product Portfolio
  24. 6.4.5 Wockhardt Ltd. Recent Developments
  25. 6.5 SAJA Pharmaceuticals
  26. 6.5.1 SAJA Pharmaceuticals Company Information
  27. 6.5.2 SAJA Pharmaceuticals Business Overview
  28. 6.5.3 SAJA Pharmaceuticals Insulin Glargine and Lispro Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 SAJA Pharmaceuticals Insulin Glargine and Lispro Product Portfolio
  30. 6.5.5 SAJA Pharmaceuticals Recent Developments
  31. 6.6 Novo Nordisk A/S
  32. 6.6.1 Novo Nordisk A/S Company Information
  33. 6.6.2 Novo Nordisk A/S Business Overview
  34. 6.6.3 Novo Nordisk A/S Insulin Glargine and Lispro Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Novo Nordisk A/S Insulin Glargine and Lispro Product Portfolio
  36. 6.6.5 Novo Nordisk A/S Recent Developments
  37. 6.7 Julphar Diabetes LLC
  38. 6.7.1 Julphar Diabetes LLC Company Information
  39. 6.7.2 Julphar Diabetes LLC Business Overview
  40. 6.7.3 Julphar Diabetes LLC Insulin Glargine and Lispro Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Julphar Diabetes LLC Insulin Glargine and Lispro Product Portfolio
  42. 6.7.5 Julphar Diabetes LLC Recent Developments
  43. 6.8 Gan & Lee Pharmaceutical Ltd.
  44. 6.8.1 Gan & Lee Pharmaceutical Ltd. Company Information
  45. 6.8.2 Gan & Lee Pharmaceutical Ltd. Business Overview
  46. 6.8.3 Gan & Lee Pharmaceutical Ltd. Insulin Glargine and Lispro Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Gan & Lee Pharmaceutical Ltd. Insulin Glargine and Lispro Product Portfolio
  48. 6.8.5 Gan & Lee Pharmaceutical Ltd. Recent Developments
  49. 6.9 Cipla Limited
  50. 6.9.1 Cipla Limited Company Information
  51. 6.9.2 Cipla Limited Business Overview
  52. 6.9.3 Cipla Limited Insulin Glargine and Lispro Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Cipla Limited Insulin Glargine and Lispro Product Portfolio
  54. 6.9.5 Cipla Limited Recent Developments
  55. 6.10 Biocon Limited
  56. 6.10.1 Biocon Limited Company Information
  57. 6.10.2 Biocon Limited Business Overview
  58. 6.10.3 Biocon Limited Insulin Glargine and Lispro Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Biocon Limited Insulin Glargine and Lispro Product Portfolio
  60. 6.10.5 Biocon Limited Recent Developments
7 North America by Country
  1. 7.1 North America Insulin Glargine and Lispro Sales by Country
  2. 7.1.1 North America Insulin Glargine and Lispro Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Insulin Glargine and Lispro Sales by Country (2021-2026)
  4. 7.1.3 North America Insulin Glargine and Lispro Sales Forecast by Country (2027-2032)
  5. 7.2 North America Insulin Glargine and Lispro Market Size by Country
  6. 7.2.1 North America Insulin Glargine and Lispro Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Insulin Glargine and Lispro Market Size by Country (2021-2026)
  8. 7.2.3 North America Insulin Glargine and Lispro Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Insulin Glargine and Lispro Sales by Country
  2. 8.1.1 Europe Insulin Glargine and Lispro Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Insulin Glargine and Lispro Sales by Country (2021-2026)
  4. 8.1.3 Europe Insulin Glargine and Lispro Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Insulin Glargine and Lispro Market Size by Country
  6. 8.2.1 Europe Insulin Glargine and Lispro Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Insulin Glargine and Lispro Market Size by Country (2021-2026)
  8. 8.2.3 Europe Insulin Glargine and Lispro Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Insulin Glargine and Lispro Sales by Country
  2. 9.1.1 Asia-Pacific Insulin Glargine and Lispro Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Insulin Glargine and Lispro Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Insulin Glargine and Lispro Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Insulin Glargine and Lispro Market Size by Country
  6. 9.2.1 Asia-Pacific Insulin Glargine and Lispro Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Insulin Glargine and Lispro Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Insulin Glargine and Lispro Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Insulin Glargine and Lispro Sales by Country
  2. 10.1.1 South America Insulin Glargine and Lispro Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Insulin Glargine and Lispro Sales by Country (2021-2026)
  4. 10.1.3 South America Insulin Glargine and Lispro Sales Forecast by Country (2027-2032)
  5. 10.2 South America Insulin Glargine and Lispro Market Size by Country
  6. 10.2.1 South America Insulin Glargine and Lispro Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Insulin Glargine and Lispro Market Size by Country (2021-2026)
  8. 10.2.3 South America Insulin Glargine and Lispro Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Insulin Glargine and Lispro Sales by Country
  2. 11.1.1 Middle East and Africa Insulin Glargine and Lispro Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Insulin Glargine and Lispro Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Insulin Glargine and Lispro Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Insulin Glargine and Lispro Market Size by Country
  6. 11.2.1 Middle East and Africa Insulin Glargine and Lispro Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Insulin Glargine and Lispro Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Insulin Glargine and Lispro Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Insulin Glargine and Lispro Value Chain Analysis
  2. 12.1.1 Insulin Glargine and Lispro Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Insulin Glargine and Lispro Production Mode & Process
  7. 12.2 Insulin Glargine and Lispro Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Insulin Glargine and Lispro Distributors
  10. 12.2.3 Insulin Glargine and Lispro Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst